🔎 Trials Near Me

ホーム › COPD › フロリダ州 › Orlando

Orlando、FLにおけるCOPDの臨床試験

Orlandoとその周辺地域(約30マイル以内)の拠点で、COPDに関する15件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。

公式研究テキスト(英語)

ここで研究参加者を募集していますか? このページの上部に表示できます — 30日間 $99 →

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

被験者募集中第3相
  • Heuer M.D. Research- Site Number : 8400018, Orlando
  • Florida Institute for Clinical Research- Site Number : 8400001, Orlando
40歳〜80歳 · 全性別 · 2026/10/01更新 · NCT07190222

To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

被験者募集中第2相
  • International Clinical Research, Altamonte Springs · 9マイル先
40歳〜85歳 · 全性別 · 2026/09/30更新 · NCT07684820

A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

被験者募集中第2相
  • Florida Institute For Clinical Research, LLC, Orlando
40歳〜75歳 · 全性別 · 2026/09/25更新 · NCT07759245

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

被験者募集中第3相
  • Omega Research Consultants - Orlando - Forest City- Site Number : 8400015, Orlando
40歳〜80歳 · 全性別 · 2026/09/22更新 · NCT07190209

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

被験者募集中
  • Orlando Health, Orlando
40歳〜80歳 · 全性別 · 2026/09/17更新 · NCT06035120

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

被験者募集中第2相
  • Research Site, Winter Park · 5マイル先
40歳以上 · 全性別 · 2026/09/09更新 · NCT07082738

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

被験者募集中第3相
  • Research Site, Winter Park · 5マイル先
40歳〜80歳 · 全性別 · 2026/09/03更新 · NCT06878261

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

被験者募集中第3相
  • Research Site, Orlando
40歳〜80歳 · 全性別 · 2026/09/03更新 · NCT06883305

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

被験者募集中第2/3相
  • Clinical Site Partners, LLC dba Flourish Research, Winter Park · 5マイル先
  • Clinical Research Specialists LLC, Kissimmee · 16マイル先
35歳〜80歳 · 全性別 · 2026/08/31更新 · NCT07363694

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

被験者募集中第3相
  • Research Site, Orlando
  • Research Site, Orlando
  • Research Site, Orlando
  • 他1件
40歳〜80歳 · 全性別 · 2026/08/26更新 · NCT06283966

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

被験者募集中第3相
  • GSK Investigational Site, Orlando
40歳〜75歳 · 全性別 · 2026/07/28更新 · NCT07177339

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

被験者募集中
  • Orlando Health, Orlando
40歳〜84歳 · 全性別 · 2026/04/24更新 · NCT06891755

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

被験者募集中第3相
  • GSK Investigational Site, Orlando
40歳〜80歳 · 全性別 · 2026/04/09更新 · NCT06961214

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

被験者募集中観察研究
  • Charter Research, Winter Park · 5マイル先
  • I.H.S Health, LLC, Kissimmee · 16マイル先
50歳以上 · 全性別 · 2025/08/05更新 · NCT06122077

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

被験者募集中
  • Alloy Clinical Research, Kissimmee · 16マイル先
30歳以上 · 全性別 · 2025/02/06更新 · NCT05204888

他の都市におけるCOPDの試験

Orlandoにおける他の研究

ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。